Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | FLT1 | P17948 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.43 |
| ▸ | FLT4 | P35916 | 3/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5444198 | 0.90 | AURKA (0.43) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL5458861 | 0.88 | FLT1 (0.41) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL5447714 | 0.87 | FLT1 (0.41) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL14564691 | 0.82 | KDR (0.66) | EGFRFLT1KDRFGFR1FLT4 | |
| Hydrochloric Acid SCHEMBL7086434 | 0.79 | EGFR (0.43) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL5457871 | 0.79 | AURKA (0.36) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL6484403 | 0.76 | AURKA (0.47) | EGFRKDRFGFR2AURKACYP1A2 | |
| SCHEMBL5495618 | 0.75 | RET (0.36) | EGFRFLT1KDRFGFR1FLT4 | |
| SCHEMBL27593927 | 0.74 | KDM4E (0.41) | EGFRFGFR2AURKACYP1A2CYP2D6 | |
| SCHEMBL14564694 | 0.73 | EGFR (0.57) | EGFRFLT1KDRFGFR1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | claimed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | claimed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | claimed |
| EP-1274692-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | claimed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | claimed |
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | disclosed |
| EP-1274692-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191308-A1 | Quinazoline compounds | CNR1, CBR1, CCR7 | EGFR 1629/4885FLT1 11/4885KDR 85/4885 |
| US-20070066633-A1 | Quinazoline compounds | CCR7, CNR1, CBR3 | EGFR 1429/4885FLT1 21/4885KDR 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.